Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ZYME | US
0.18
1.45%
Healthcare
Biotechnology
30/06/2024
04/10/2024
12.57
12.37
12.60
12.35
Zymeworks Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab a human epidermal growth factor receptor 2 (HER2) that is in Phase 1 Phase 2 and Phase 3 clinical trials for the treatment of biliary tract gastroesophageal adenocarcinomas breast colorectal and endometrial cancers; and zanidatamab zovodotin a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co. Ltd.; Janssen Biotech Inc.; LEO Pharma A/S; Iconic Therapeutics Inc.; Merck Sharp & Dohme Research GmbH; and Atreca Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver Canada.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
20.8%1 month
27.1%3 months
34.8%6 months
36.9%-
-
2.17
0.05
0.04
0.34
9.13
-
-115.55M
893.07M
893.07M
-
-133.03
-
174.80
-26.32
4.87
5.91
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.19
Range1M
2.09
Range3M
4.94
Rel. volume
0.79
Price X volume
5.60M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Array BioPharma Inc | ARRY | Biotechnology | 6.45 | 979.92M | 0.62% | 67.30 | 117.68% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 4.23 | 941.03M | -2.98% | n/a | 29.02% |
Silence Therapeutics plc | SLN | Biotechnology | 18.64 | 933.49M | 1.30% | n/a | 0.16% |
Prothena Corporation plc | PRTA | Biotechnology | 16.86 | 906.74M | 1.08% | n/a | 2.08% |
Applied Therapeutics Inc | APLT | Biotechnology | 7.7 | 884.31M | -8.22% | n/a | 0.30% |
Cronos Group Inc | CRON | Biotechnology | 2.24 | 856.31M | 3.70% | n/a | 0.19% |
iShares $ Corp Bond ETF USD Dist | LQDA | Biotechnology | 10.03 | 846.31M | 0.25% | n/a | 4.70% |
CARGO Therapeutics Inc. Common Stock | CRGX | Biotechnology | 17.77 | 815.72M | -1.44% | n/a | 6.45% |
Adeptus Health Inc | ADPT | Biotechnology | 5.52 | 814.05M | 7.39% | n/a | 93.65% |
Nuvation Bio Inc | NUVB | Biotechnology | 2.41 | 806.82M | 9.05% | n/a | 112.61% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.34 | 0.76 | Cheaper |
Ent. to Revenue | 9.13 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.17 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 34.79 | 74.67 | Lower Risk |
Debt to Equity | 0.05 | -1.82 | Expensive |
Debt to Assets | 0.04 | 0.26 | Cheaper |
Market Cap | 893.07M | 3.73B | Emerging |